A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

European Heart Journal

Volumn 36, Issue 7, 2015, Pages 434-439

  McMurray, John ^a   Packer, Milton ^b   Desai, Akshay ^c   Gong, Jianjian ^d   Greenlaw, Nicola ^e   Lefkowitz, Martin ^d   Rizkala, Adel ^d   Shi, Victor ^d   Rouleau, Jean ^f   Solomon, Scott ^c   Swedberg, Karl ^g,h   Zile, Michael R ⁱ   Andersen, Karl ^j   Arango, Juan Luis ^k   Arnold, Malcolm ^l   Bělohlávek, Jan ^m   Böhm, Michael ⁿ   Boytsov, Sergey ^o   Burgess, Lesley ^p   Cabrera, Walter ^q   Chen, Chen Huan ^r,s   Erglis, Andrejs ^t   Fu, Michael ^u   Gomez, Efrain ^v   Gonzalez, Angel ^w   Hagege, Albert Alain ^x   Katova, Tzvetana ^y   Kiatchoosakun, Songsak ^z   Kim, Kee Sik ^aa   Bayram, Edmundo ^ab   Martinez, Felipe ^ac   Merkely, Bela ^ad   Mendoza, Iván ^ae   Mosterd, Arend ^af   Negrusz Kawecka, Marta ^ag   Peuhkurinen, Keijo ^ah   Ramires, Felix ^ai   Refsgaard, Jens ^aj   Senni, Michele ^ak   Sibulo, Antonio S ^al   Silva Cardoso, José ^am   Squire, Iain ^an   Starling, Randall C ^ao   Vinereanu, Dragos ^ap   Teerlink, John R ^aq   Wong, Raymond ^ar   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f MONTREAL HEART INSTITUTE   (Canada)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j UNIVERSITY OF ICELAND   (Iceland)

^k Guatemalan Heart Institute   (Guatemala)

^l WESTERN UNIVERSITY   (Canada)

^m CHARLES UNIVERSITY   (Czech Republic)

ⁿ SAARLAND UNIVERSITY   (Germany)

^o NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

^p STELLENBOSCH UNIVERSITY   (South Africa)

^q Clinica Vesalio   (Peru)

^r NATIONAL YANG MING UNIVERSITY   (Taiwan)

^s TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^t UNIVERSITY OF LATVIA   (Latvia)

^u SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^v Division of Cardiovascular Surgery   (Colombia)

^w Instituto dominicano de Cardiología   (Dominican Republic)

^x HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^y National Cardiology Hospital   (Bulgaria)

^z KHON KAEN UNIVERSITY   (Thailand)

^aa Medical Center 3056 6   (South Korea)

^ab Fundación Cardiovascular de Aguascalientes   (Mexico)

^ac Fundacion Rusculleda   (Argentina)

^ad SEMMELWEIS UNIVERSITY   (Hungary)

^ae UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^af MEANDER MEDICAL CENTER   (Netherlands)

^ag WROCLAW MEDICAL UNIVERSITY   (Poland)

^ah UNIVERSITY OF EASTERN FINLAND   (Finland)

^ai UNIVERSITY OF SÃO PAULO   (Brazil)

^aj VIBORG HOSPITAL   (Denmark)

^ak PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^al St LukesHeart Institute   (Philippines)

^am Center for Medical Education   (Portugal)

^an UNIVERSITY OF LEICESTER   (United Kingdom)

^ao LERNER RESEARCH INSTITUTE   (United States)

^ap CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^aq UNIVERSITY OF CALIFORNIA   (United States)

^ar Department of Cardiology National University Hearty Centre ^*  (Singapore)

more..

Author keywords

Angiotensin II; Heart failure; Natriuretic peptides

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLACEBO; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HAZARD RATIO; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; COMPARATIVE STUDY; HOSPITALIZATION; MORTALITY; PLACEBO EFFECT; STATISTICS AND NUMERICAL DATA;

AGED; AMINOBUTYRATES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; ENALAPRIL; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; TETRAZOLES; TREATMENT OUTCOME;

EID: 84928634952     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu455     Document Type: Article

References (14)

1. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartancompared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355: 1582-1587.
2. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906. Erratum in N Engl J Med 2004;350:203.
3. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-760.
4. Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, Desai A, Gimpelewicz C, Kandra A, Reimund B, Rattunde H, Armbrecht J. ATMOSPHERE Investigators. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to MinimizeOutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011;13:107-114.
5. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, ShiVC, Solomon SD, Swedberg K, Zile MR. PARADIGM-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J med 2014;371:993-1004.
6. Hasselblad V, Kong DF. Statistical methods for comparison to placebo in activecontrol trials. Drug Info J 2001;35:435-449.
7. Durrleman S, Chaikin P. The use of putative placebo in active control trials: two applications in a regulatory setting. Stat Med 2003;22:941-952.
8. Fisher LD, Gent M, Büller HR. Active-control trials:howwould anewagent compare with placebo?A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J 2001;141:26-32.
9. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325: 293-302.
10. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARMAlternative trial. Lancet 2003;362:772-776.
11. James Hung HM,Wang SJ, Tsong Y, Lawrence J, O'Neil RT. Some fundamental issues with non-inferiority testing in active controlled trials. Stat Med 2003;22:213-225.
12. Kaul S, Diamond GA,Weintraub WS. Trials and tribulations of non-inferiority: the ximelagatran experience. J Am Coll Cardiol 2005;46:1986-1995.
13. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
14. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013ACCF/AHAguideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240-e327.